NCT03346135: Phase 2: Daratumumab After Stem Cell Transplant in Treating Patients With Myeloma NDMM

• Multiple Myeloma Research Consortium

• NCT03346135: Phase 2: Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
  

Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma

This phase II trial studies how well daratumumab after a stem cell transplant works in treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill cancer cells that are left after chemotherapy.

Sponsor:

City of Hope Medical Center

Collaborator:

National Cancer Institute (NCI)

---

ClinicalTrials.gov Identifier: NCT03346135

Official Title: A Multicenter, Open-Label, Single Arm, Phase II Study of Daratumumab as Consolidation/Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma

First Posted: November 17, 2017

https://clinicaltrials.gov/ct2/show/NCT03346135

---

Procedure: Autologous Hematopoietic Stem Cell Transplantation

Biological: Daratumumab

Other: Laboratory Biomarker Analysis

Drug: Melphalan

---